Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline
Guidelines for post-mastectomy radiation include patients who received neoadjuvant therapy, with or without residual disease after treatment. A good topic to review.
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial
Author(s): Antonio Llombart-Cussac, MD, PhD1,2,3; Catherine Harper-Wynne, MD, PhD4; Antonia Perelló, MD, PhD5; Audrey Hennequin, MD, PhD6; Adela Fernández-Ortega, MD, PhD7; Marco Colleoni, MD, PhD8; Sara Marín, MD, PhD2; Vanesa Quiroga, MD, PhD9; Jacques Medioni, MD, PhD10,11; Vega Iranzo, MD, PhD12,13; Duncan Wheatley, MD, PhD14; Sonia del Barco Berrón, MD, PhD15; Antonio Antón, MD, PhD16,17; Erion Dobi, MD, PhD18; Manuel Ruiz-Borrego, MD, PhD19; Daniel Alcalá-López, PhD1; Jhudit Pérez-Escuredo, PhD1; Gabriele Antonarelli, MD, PhD20,21; Miguel Sampayo-Cordero, PhD1; José Manuel Pérez-García, MD, PhD1,22; Javier Cortés, MD, PhD1,22,23,24;
Source: DOI:10.1200/JCO-24-01865
Dr. Maen Hussein's Thoughts
Adding Palbociclib did not help, revealing that there is no need to continue with different hormonal therapy than the one used in first line. It also added more toxicity.
PURPOSE
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HER2-negative) advanced breast cancer (ABC). However, there is no definitive consensus on the preferred second-line treatment option. The PALMIRA trial investigated whether palbociclib rechallenge with an alternative ET would improve the antitumor activity in patients progressing after a first-line palbociclib-containing regimen.
METHODS
This international, randomized, open-label, phase II study enrolled 198 patients with hormone receptor–positive/HER2-negative ABC with disease progression after first-line palbociclib plus ET (aromatase inhibitor or fulvestrant). Patients were eligible if they showed clinical benefit to the previous regimen (response or stable disease ≥24 weeks) or had progressed on a palbociclib-based therapy in the adjuvant setting. Patients were randomly assigned (2:1 ratio) to either palbociclib rechallenge plus second-line ET (fulvestrant or letrozole) or second-line ET alone. Stratification factors were previous ET and visceral involvement. The primary end point was investigator-assessed progression-free survival (PFS).
RESULTS
Between April 2019 and October 2022, 136 and 62 patients were randomly assigned to palbociclib plus ET or ET alone, respectively. Median investigator-assessed PFS was 4.9 months (95% CI, 3.6 to 6.1) with palbociclib plus ET versus 3.6 months (95% CI, 2.5 to 4.2) with ET alone (hazard ratio, 0.84 [95% CI, 0.66 to 1.07]; P = .149). Grade ≥3 treatment-emergent adverse events were higher with palbociclib plus ET (47.4% v 10.0%), without new safety signals.
CONCLUSION
Palbociclib rechallenge plus an alternative ET did not significantly improve PFS compared with ET alone in patients with hormone receptor–positive/HER2-negative ABC progressing on a first-line palbociclib-based ET regimen.
Author Affiliations
1Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; 2Hospital Arnau de Vilanova, FISABIO, Valencia, Spain; 3Translational Oncology Group, Medicine Department, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, Alfara del Patriarca, Spain; 4Maidstone Hospital – Kent Oncology Centre, Maidstone, United Kingdom; 5Hospital Universitari Son Espases, Palma de Mallorca, Spain; 6Centre Georges François Leclerc, Dijon, France; 7Institut Català d’Oncologia L’Hospitalet (ICO), Barcelona, Spain; 8IEO, Instituto Europeo di Oncologia, IRCCS, Milan, Italy; 9Institut Català d’Oncologia Badalona (ICO), Barcelona, Spain; 10Hôpital Européen Georges Pompidou, Paris, France; 11University Paris Cité, Paris, France; 12Consorci Hospital General Universitari de València, Valencia, Spain; 13Universitat de València, Valencia, Spain; 14Royal Cornwall Hospital NHS Trust, Cornwall, United Kingdom; 15Institut Català d’Oncologia Girona (ICO), Girona, Spain; 16Hospital Universitario Miguel Servet, Zaragoza, Spain; 17Instituto Investigación Sanitaria Aragón (IISA), Universidad de Zaragoza (UNIZAR), Zaragoza, Spain; 18Hôpital Jean Minjoz, Doubs, France; 19Hospital Universitario Virgen del Rocío, Sevilla, Spain; 20Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; 21Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy; 22International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain; 23Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain; 24IOB Madrid, Hospital Beata María Ana, Madrid, Spain;Related Articles
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
Our site participated in this study, where patients were tested for ESR1 mutations via circulating tumor DNA (ctDNA). Those who tested positive were switched to camizestrant (Cami), which demonstrated improved progression-free survival.
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly utilizes the ubiquitin–proteasome system. It was compared to fulvestrant in patients who had received one prior line of hormonal therapy with a CDK4/6 inhibitor. Among patients with ESR1 mutations, Vepdegestrant demonstrated a median progression-free survival (PFS) of 5.0 months versus 2.1 months with fulvestrant. In the overall population, the median PFS was 3.8 months for Vepdegestrant and 3.6 months for fulvestrant, indicating that the drug showed particular efficacy in tumors harboring ESR1 mutations.
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
Elinzanitant, a neurokinin-targeted therapy, has been shown to reduce vasomotor symptoms compared to placebo. These symptoms are one of the reasons some of my patients discontinue aromatase inhibitor (AI) therapy, so Elinzanitant presents a promising alternative to help manage these side effects. Additionally, Fezolinetant is already approved and available on the market.
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
The INAVO120 trial evaluated inavolisib + palbociclib–fulvestrant vs placebo + palbociclib–fulvestrant in patients with PIK3CA-mutated, HR+/HER2– advanced breast cancer progressing on or shortly after adjuvant endocrine therapy (ET). Inavolisib significantly improved overall survival (OS) (34.0 vs 27.0 mo) and progression-free survival (PFS) (17.2 vs 7.3 mo), with a higher objective response rate (ORR) (62.7% vs 28.0%) and longer DoR (19.2 vs 11.1 mo). Toxicities were manageable but included more hyperglycemia (63.4%), stomatitis (55.3%), GI, and ocular AEs. Bottom line: this triplet sets a new bar for first-line PIK3CA-mutant HR+ MBC, but we’ll need to stay vigilant about metabolic and mucosal side effects as we bring it into practice.